Nov 4 2014 saw SUM miss on revenues & earnings resulting in an immediate 19% drop in share value. It appeared to bottom out on Jan 21 @ $6.60 26% below it's high back in Nov prior to the last report.
Since then it has slowly started to regain some momentum on sporadic trading which has increased over the past couple of days. It is being covered by a number of analysts who for the most part are fairly bullish on expectations with an average target price of $8.94.
On Dec 1st you said "The most recent quarter was not the greatest and concern over future growth has arisen. We would not consider the valuation as cheap but some decent growth is expected."
Your advice was to not rush in and to wait and see what happens with the next quarter.
Right now I am slightly ahead with SUM scheduled to report March 18.
I was wondering if you could tell us what the street expects, whether you would consider SUM a Sell/Hold/Buy, and what your advice for me would be moving forward. My weighting is 3.6%.
Q: Keep up the great work.
Quite a while ago you gave me 2 names AYA and SYZ, both did very well as you know,(although SYZ is off lately)
Could you please give me just one U.S. stock the might replicate either of the above - preferably AYA.
This is not part of my well balanced portfolio its just a bit of US cash I need to do better on than where it currently sits, this can be more of a high risk name.
Sylogist declared quite good results and they did an equity offering for 11 cad. They did a few acquistions too if I am not mistaken. Conventional wisdom states that a company grows by acquistions case in point csu,valient, Amaya so why is sylogist not following. They also increased their dividend what else do they have to do to increase their share value your
comments will be appreciated.
Q: What's your analysis of CSU's earnings? It appears to be a beat on most metrics. Any comments on integration of TSS acquisition and impact of strong USD on earnings. Thanks
Q: I would appreciate your thoughts on this stock. The company is provides cloud based services to life sciences industry. Does the company have growth potential?
Thanks
Q: Investors are loving Apple and neglecting Google these days. My position in Apple has doubled. It is still not overweight in the portfolio. Thinking of selling half of the Apple position to diversify into Google. Google has stalled lately and there is an expectation of a capital return program that may get the stock moving. Or just leave the Apple position alone?
Q: Can you please comment on Sylogist results released this evening.Do you see an improving trend ? Any thoughts on : "During the past year we deferred opportunities in our Canadian public sector unit and payment solutions operations to invest in our foundational technology, moving Sylogist products well ahead of market competitors. We are encouraged by the early financial success of these investments as noted in our MD&A"
Q: Since your last update on NeuLion the shares improved a little, then fell back once again.
I know it is not a long period of time since the last update but I am wondering if your views have changed. In particular I am think about selling Neulion and buying Espial. Your thoughts on this swith would be appreciated
Q: What do you think of cantor fitzgerald's take on Tecsys:
http://www.cantechletter.com/2015/02/tecsys-double-triple-says-cantor-fitzgerald/
Too optimistic? Should I switch my Sylogist for TCS for a three to five year hold? Thanks again.